




INSTITUTO DE INVESTIGACIONES
BIOMÉDICAS



Multi-scale mathematical modelling of epithelial tissues to uncover the mechanisms of onset, progression, prevention and reversion of complex diseases

Elisa Domínguez-Hüttinger,
Instituto de Investigaciones Biomédicas, UNAM




Systems Biology
IIB-UNAM

On the menu today:

Systems biology for the analysis of
Complex epithelial tissue diseases:

What? Why? How?

Complex epithelial tissue diseases: challenges




(1) Many possible combinations, synergism

(2) Pathogenic mechanisms are unclear


(3) Slow pathological progression

(4) Negative side effects of treatments that are often ineffective


How can we understand, **diagnose, prevent** and **revert**?)?




What is systems biology?




Systems biology pipeline



Model to agree with experimental data



Adapted from Domínguez-Hüttinger, E. et al., 2017. *Front. Physiol.* 8: 115




(What?)

Why?

(How?)


Our working example:



System of interacting pathogens, immune cells and epithelial tissue.


Figure adapted from:
Domínguez-Hüttinger, E. et al., 2017. *Front. Physiol.* 8:115.

Key clinically relevant questions



- What is the (clinical) **outcome** of this system?
- How is it affected by genetic or environmental **risk factors**?
- How can systemic infection be **prevented**?
- How could the risk of antibiotics resistance be **minimized**?

What are the challenges?



Complex and non-linear

- Synergy between risk factors (network-as-buffer)
- Negative side effects of treatments (propagation of disturbances)


Dynamical

- Multiple processes co-occurring at different (temporal) scales
- Disease progression

Quantitative:

- Dose-dependency of qualitative transitions
- Need for optimization of treatments

How can systems biology help?



~




- Simulate what can't be measured
- Perturbation analysis (of risk factors)
- Optimization of treatments
- Predicting the infectious dynamics
- Identify vulnerable patient cohorts

What?

Why?

How?

Step 1: Formalization



=

$$\begin{aligned}\frac{dS_a(t)}{dt} &= \frac{\kappa_S}{\mu_S} S_a(t)(1 - S_a(t)) - \frac{\theta_S}{1 + \epsilon_{SB}B(t)} S_a(t) \\ &\quad - \phi_{NS}N(t)S_a(t) - \phi_{MS}M(t)S_a(t), \\ \frac{dS_v(t)}{dt} &= \kappa_S S_v(t) + \frac{\theta_S}{1 + \epsilon_{SB}B(t)} S_a(t) - \frac{\delta_S}{K + S_v(t)} S_v(t), \\ \frac{dN(t)}{dt} &= \alpha \frac{R(S_a(t))}{(1 + \epsilon_{NB}B(t))(1 + \epsilon_{NM}M(t))} N_v - \delta_N N(t), \\ \frac{dM(t)}{dt} &= \beta \frac{N(t)}{1 + \epsilon_{MB}B(t)} M_v - \delta_M M(t), \\ \frac{dB(t)}{dt} &= \frac{\kappa_B}{1 + \epsilon_{BS}R(S_a(t))} B(t)(\tilde{B} - B(t)) \\ &\quad - \phi_{SB}R(S_a(t))B(t) - \phi_{NB}N(t)B(t).\end{aligned}$$


Non-linear network
of feedback interactions:
A dynamical system

$$R(S_a(t)) = \begin{cases} R_{\text{off}} & \text{if } S_a(t) < S^- \text{ or } \{S^- \leq S_a(t) < S^+ \text{ and} \\ & R(S_a(t^-)) = R_{\text{off}}\}, \\ R_{\text{on}} & \text{if } S_a(t) \geq S^+ \text{ or } \{S^- \leq S_a(t) < S^+ \text{ and} \\ & R(S_a(t^-)) = R_{\text{on}}\}, \end{cases}$$


Domínguez-Hüttinger, E. et al.,
2017. Front. Physiol. 8:115.

Integration of experimental data


(i) Barrier function



(ii) Pathogen load




(iii) Neutrophils




(II) System - dependent parameters: Sub-systems


(i) Barrier-Pathogen




(ii) Pathogen-Neutrophil



(iii) Neutrophil-Barrier








(III) In vivo parameters



$$\begin{aligned} \frac{dS_a(t)}{dt} &= \frac{\kappa_S}{\mu_S} S_a(t)(1 - S_a(t)) - \frac{\theta_S}{1 + \epsilon_{SB}B(t)} S_a(t) \\ &\quad - \phi_{NS}N(t)S_a(t) - \phi_{MS}M(t)S_a(t), \\ \frac{dS_v(t)}{dt} &= \kappa_S S_v(t) + \frac{\theta_S}{1 + \epsilon_{SB}B(t)} S_a(t) - \frac{\delta_S}{K + S_v(t)} S_v(t), \\ \frac{dN(t)}{dt} &= \alpha \frac{R(S_a(t))}{(1 + \epsilon_{NB}B(t))(1 + \epsilon_{NM}M(t))} N_v - \delta_N N(t), \\ \frac{dM(t)}{dt} &= \beta \frac{N(t)}{1 + \epsilon_{MB}B(t)} M_v - \delta_M M(t), \\ \frac{dB(t)}{dt} &= \frac{\kappa_B}{1 + \epsilon_{BS}R(S_a(t))} B(t)(\tilde{B} - B(t)) \\ &\quad - \phi_{SB}R(S_a(t))B(t) - \phi_{NB}N(t)B(t). \end{aligned}$$

$$R(S_a(t)) = \begin{cases} R_{off} & \text{if } S_a(t) < S^- \text{ or } \{S^- \leq S_a(t) < S^+ \text{ and} \\ & R(S_a(t^-)) = R_{off}\}, \\ R_{on} & \text{if } S_a(t) \geq S^+ \text{ or } \{S^- \leq S_a(t) < S^+ \text{ and} \\ & R(S_a(t^-)) = R_{on}\}. \end{cases}$$


Step 2: Parametrization and validation



(+simulation of variables that can't be measured)

Domínguez-Hüttinger, E. et al., 2017. Front. Physiol. 8:115.

(cont. Parametrization and validation)



(model agrees with 13 independent datasets)

Domínguez-Hüttinger, E. et al.,
2017. Front. Physiol. 8:115.

Step 3: Model analysis

(a) Perturbation analysis


Question: How robust is the system?

- How much do we have to hit the system until the functionality is lost?
- Quantification of the fragility of the system.



(a) Perturbation analysis

Environmental
risk factors



Mutations
SNPs









Figure adapted from
Mayo, A.E. et al., 2006. *LoS Biology*, 4(4), pp.555–561.

Homeostasis: a robust property of the system



Domínguez-Hüttinger, E. et al.,
2017. Front. Physiol. 8:115.



Step 3: Model analysis


(b) Sensitivity analysis

Question: What causes the loss of homeostasis?

- Computational tools to identify the changes in parameters that are most likely to result in disease



Mechanisms of dysbiosis



Most sensitive parameters:

- rate of bacterial transmigration through the barrier (θ_S),
- bacterial carrying capacity (μ_S),
- killing rate of bacteria by macrophages (ϕ_{MS})

Domínguez-Hüttinger, E. et al.,
2017. Front. Physiol. 8:115.

Less sensitive:

- propensity to develop sepsis (S_V)
- unresolved host responses (R)

Step 3: Model analysis

(c) Bifurcation analysis


Question:

How do the the risk factors affect the infectious dynamics?





Step 3: Model analysis

(c) Bifurcation analysis



Domínguez-Hüttinger, E. et al.,
2017. Front. Physiol. 8:115.

Step 4: Checking consistency of predictions with experimental data




Domínguez-Hüttinger, E. et al.,
2017. Front. Physiol. 8:115.


Consistent with experimental data:
Andonegui et al, Shock 2009

Using the model for treatment optimization

(A) Optimal treatments for reversion of immune scarring (Patient cohort 1) - apically applied antibiotics



(B) Optimal antibiotics dose for prevention of sepsis (Patient cohort 2) - antibiotics in the blood vessel



Domínguez-Hüttinger, E. et al., 2017. Front. Physiol. 8:115.

Tackling antibiotics resistance!

From description to
prediction



Robustness assessment



Prevention of
catastrophes






Design of optimal treatments

Conclusions

Black box (a bit more) illuminated



Systems biology to understand, prevent and optimally treat complex epithelial tissue diseases




Mathematical Modeling of *Streptococcus pneumoniae* Colonization, Invasive Infection and Treatment

Elisa Domínguez-Hüttinger^{1,2*}, Neville J. Boon¹, Thomas B. Clarke^{3*} and Reiko J. Tanaka^{1*}


¹ Department of Bioengineering, Imperial College London, London, UK, ² Instituto de Ecología, Universidad Nacional Autónoma de México, Mexico City, Mexico, ³ Department of Medicine, Imperial College London, London, UK



Imperial College
London



Complex epithelial tissue diseases – a systems biology perspective



1. Guillem Hurault, E. Domínguez-Hüttinger, ..., R. J. Tanaka et al., 2020, CEA
2. G. Tanaka, E. Domínguez-Hüttinger, ..., R. J. Tanaka. *Journal of Theoretical Biology*, 448: 66-79
3. P. Christodoulides, ..., E. Domínguez-Hüttinger, ..., R. J. Tanaka. 2017. *Phil. Trans. R. Soc. A.*, 375: 20160285.
4. E. Domínguez-Hüttinger, ..., R. J. Tanaka, 2017. *Front. Physiol.*, 8: (115), pp.1–14.
5. F. Méndez-López, ..., E. Domínguez-Hüttinger, ... E. Álvarez-Buylla, 2017. *BMC Syst Biol.*, 11(24), pp.1–15.
6. E. Domínguez-Hüttinger, ..., R. J. Tanaka. 2017. *J. Allergy Clin. Immunol* 139:1861-72.
7. M. D. A. van Logtestijn, E. Domínguez-Hüttinger, ..., R. J. Tanaka. 2015. *PLoS ONE* 10(2):e0117292.
8. Domínguez-Hüttinger E., ..., R.J. Tanaka. 2013. *Interface Focus* 3:20120090
9. Elena R. Álvarez-Buylla Rocas, ..., Elisa Domínguez-Hüttinger, and Mariana Esther Martínez-Sánchez. *Modeling Methods for Medical Systems Biology - Regulatory Dynamics Underlying the Emergence of Disease Processes*. Editorial: Springer. Serie: Advances in Experimental Medicine and Biology (2018)




Acknowledgements




RIKEN

Imperial College
London



Cinvesta



INSTITUTO NACIONAL DE
CIENCIAS MÉDICAS
Y NUTRICIÓN
SALVADOR ZUBIRÁN



Imperial College
London




LaNSBioDyT
LABORATORIO NACIONAL
DE SOLUCIONES BIOMIMÉTICAS PARA DIAGNÓSTICO Y TERAPIA



UNIVERSIDAD TECNICA
FEDERICO SANTA MARIA



Thank you for your attention.



elisa.dominguez@iibiomedicas.unam.mx